Protalix BioTherapeutics Inc. reported positive Phase III data for its enzyme replacement therapy Uplyso (taliglucerase alfa), staking its claim as another serious contender in the Gaucher disease space held almost exclusively by Genzyme Corp.'s Cerezyme (imiglucerase). (BioWorld Today) Read More
